Please select the option that best describes you:
Are there any molecular predictors for response to chemoimmunotherapy for patients with ES-SCLC?
Are you routinely performing molecular sequencing? Would you modify your treatment approach in first or later lines based on PDL1 status?
Answer from: Medical Oncologist at Academic Institution
The short answer is no, there are no validated, clinically useful biomarkers to predict benefit (or lack of benefit) with immune checkpoint inhibitors for patients with SCLC.Early studies, including KEYNOTE-028 and KEYNOTE-158, suggested that PD-L1 TPS (tumor proportional score) correlated with resp...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
No. Molecular testing is something we often do but I would not consider it standard. PD-L1 has not correlated with outcomes for first-line chemo-immunotherapy. Expression of transcriptional regulators is under investigation but has not yet been shown to impact care.
Comments
Medical Oncologist at New York Cancer & Blood Specialists
What about TMB?
What about TMB?
Answer from: Medical Oncologist at Community Practice
Unless you test you will never find it. Certain tumor agnostic therapies such as for NTRK can be useful to patients. I will test for good performance status at progression and use clinical judgement in the absence of clinical trials.